Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment

Published: December 16 2016
Abstract Views: 3023
PDF: 778
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg/week. After six months of treatment repeated testing showed no uptake of the discs and vertebral bodies.

Altmetrics

Downloads

Download data is not yet available.

Citations

M. Benucci, Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze
Internal Medicine

How to Cite



Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment. (2016). Reumatismo, 68(3), 163-165. https://doi.org/10.4081/reumatismo.2016.911

Similar Articles

11-20 of 84

You may also start an advanced similarity search for this article.